Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2011 Oct 27;5420:7150-64. doi: 10.1021/jm200739e.
Show Gene links
Show Anatomy links
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.
Wang L
,
Desmoulin SK
,
Cherian C
,
Polin L
,
White K
,
Kushner J
,
Fulterer A
,
Chang MH
,
Mitchell-Ryan S
,
Stout M
,
Romero MF
,
Hou Z
,
Matherly LH
,
Gangjee A
.
???displayArticle.abstract???
2-Amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine antifolates with a thienoyl side chain (compounds 1-3, respectively) were synthesized for comparison with compound 4, the previous lead compound of this series. Conversion of hydroxyl acetylen-thiophene carboxylic esters to thiophenyl-α-bromomethylketones and condensation with 2,4-diamino-6-hydroxypyrimidine afforded the 6-substituted pyrrolo[2,3-d]pyrimidine compounds of type 18 and 19. Coupling with l-glutamate diethyl ester, followed by saponification, afforded 1-3. Compound 3 selectively inhibited the proliferation of cells expressing folate receptors (FRs) α or β, or the proton-coupled folate transporter (PCFT), including KB and IGROV1 human tumor cells, much more potently than 4. Compound 3 was more inhibitory than 4 toward β-glycinamide ribonucleotide formyltransferase (GARFTase). Both 3 and 4 depleted cellular ATP pools. In SCID mice with IGROV1 tumors, 3 was more efficacious than 4. Collectively, our results show potent antitumor activity for 3 in vitro and in vivo, associated with its selective membrane transport by FRs and PCFT over RFC and inhibition of GARFTase, clearly establishing the 3-atom bridge as superior to the 1-, 2-, and 4-atom bridge lengths for the activity of this series.
???displayArticle.pubmedLink???
21879757
???displayArticle.pmcLink???PMC3209708 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Beardsley,
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
1989, Pubmed
Beardsley,
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
1989,
Pubmed
Budman,
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
2001,
Pubmed
Corbett,
Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
1997,
Pubmed
Deng,
Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.
2009,
Pubmed
Deng,
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
2008,
Pubmed
Desmoulin,
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
2010,
Pubmed
,
Xenbase
Elnakat,
Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy.
2004,
Pubmed
Gibbs,
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
2005,
Pubmed
Gunshin,
Cloning and characterization of a mammalian proton-coupled metal-ion transporter.
1997,
Pubmed
,
Xenbase
LOWRY,
Protein measurement with the Folin phenol reagent.
1951,
Pubmed
Mackenzie,
Divalent metal-ion transporter DMT1 mediates both H+ -coupled Fe2+ transport and uncoupled fluxes.
2006,
Pubmed
,
Xenbase
Matherly,
Human reduced folate carrier: translation of basic biology to cancer etiology and therapy.
2007,
Pubmed
McLeod,
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
2000,
Pubmed
Moran,
The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
1989,
Pubmed
Polin,
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.
1997,
Pubmed
Qiu,
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
2006,
Pubmed
,
Xenbase
Racanelli,
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
2009,
Pubmed
Ray,
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
1993,
Pubmed
Rosowsky,
PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates.
1999,
Pubmed
Salazar,
The folate receptor: what does it promise in tissue-targeted therapeutics?
2007,
Pubmed
Taylor,
Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.
1985,
Pubmed
Unal,
The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1.
2009,
Pubmed
,
Xenbase
Varela-Moreiras,
Long-term folate deficiency alters folate content and distribution differentially in rat tissues.
1992,
Pubmed
Wang,
Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
2010,
Pubmed
Zhao,
Resistance to antifolates.
2003,
Pubmed
Zhao,
A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
2004,
Pubmed
Zhao,
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.
2009,
Pubmed
Zhao,
The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed.
2007,
Pubmed
